Genetic polymorphisms associated with childhood AML

Bookmark and Share
Published: 26 Sep 2016
Views: 2117
Rating:
Save
Dr Gisele Brisson - Instituto Nacional de Cancer, Rio de Janeiro, Brazil

Dr Brisson speaks with ecancertv at Childhood Cancer 2016 about polymorphisms in enzymes required for the benzene processing pathway resulting in variable susceptibility to acute myeloid leukaemia (AML).

She highlights NQO1 and GSTM1 polymorphisms were associated with increased risk to differing subtypes of childhood leukaemia.

 

Childhood Cancer 2016

Genetic polymorphisms associated with childhood AML

Dr Gisele Brisson - Instituto Nacional de Cancer, Rio de Janeiro, Brazil


This work is about genetic susceptibility in childhood acute myeloid leukaemia and it’s based on the fact that some environmental exposures were associated with childhood AML. We know that those environmental toxicants need to be metabolised by several enzymes in our body and those enzymes are polymorphic. Because of that we have different ways of metabolising those substances among the individuals which means that there are different genetic susceptibilities among individuals. So this work is based on this fact and so we chose some genetic polymorphisms that are in the benzene pathway because we know that benzene is carcinogenic to humans and causes AML and other haematological disorders so we chose to pick this pathway to study.

What did you find?

We found that EPHX1, NQ01 and GSTM1 polymorphisms were associated with childhood AML risk in our study, mainly with some specific AML subtypes which were CBF beta, MYH11 and APL, promyelocytic leukaemia, and also FLT3 mutations, AML with FLT3 mutations.

What conclusions can be drawn from this?

The conclusion is that genetic susceptibility plays an important role on AML’s risk in children in our population. This study is very important because there are very few studies about genetic susceptibility in AML, most are regarding ALL which is the most frequent subtype of leukaemia in children. So this is important because of the few information regarding this subject, AML. This is particularly useful for our population – the incidence rates of AML, of childhood AML, in Brazil are slightly higher than high income countries like the USA or the majority of countries here in Europe. So this genetic background could be one of the answers of why our incidence rates of AML are this different from other countries.

Related Videos

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanc...
Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )
11 Sep 2022
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan
Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, US...
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Sep 2022
How air pollution may trigger lung cancer in never-smokers
Prof Charles Swanton - Francis Crick Institute, London, England
How air pollution may trigger lung cancer in never-smokers ( Prof Charles Swanton - Francis Crick Institute, London, England )
10 Sep 2022
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper resp...
Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )
6 Jun 2022
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-defic...
Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )
5 Jun 2022
Integrated genomic analysis identifies UBTF tandem duplications as a subtype-def...
Dr Masayuki Umeda - St. Jude Children's Research Hospital, San Francisco, USA
Integrated genomic analysis identifies UBTF tandem duplications as a subtype-defining lesion in paediatric AML ( Dr Masayuki Umeda - St. Jude Children's Research Hospital, San Francisco, USA )
14 Dec 2021
Pathogenesis of colon adenocarcinoma in Kerala, India
Dr Prasanth Ariyannur - Amrita Institute of Medical Sciences and Research Center...
Pathogenesis of colon adenocarcinoma in Kerala, India ( Dr Prasanth Ariyannur - Amrita Institute of Medical Sciences and Research Center, Kochi India )
12 Oct 2021
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )
10 Jun 2021